<DOC>
	<DOCNO>NCT01469234</DOCNO>
	<brief_summary>The purpose study determine onset action two commercially available over-the-counter antihistamine ( Loratadine Fexofenadine ) model seasonal allergic rhinitis ( SAR ) . Participants undergo sensitization exposure Mountain Cedar ( juniperus ashei ) pollen Biogenics Research Chamber ; demonstrate adequate allergic response determine Major Symptom Complex ( MSC ) score receive drug .</brief_summary>
	<brief_title>A Study Onset Action Loratadine Fexofenadine Participants With Seasonal Allergic Rhinitis ( P08712 )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Fexofenadine</mesh_term>
	<mesh_term>Loratadine</mesh_term>
	<mesh_term>Terfenadine</mesh_term>
	<criteria>Female participant child bear potential must demonstrate negative urine pregnancy test Screening ( Visit 1 ) Visit 4 ( prior randomization ) agree use ( and/or partner use ) 2 acceptable method birth control begin Screening visit throughout study . Willing stop use current decongestant allergy medication start washout period ( Visit 1 ) trial . Documented history participantreported history seasonal allergic rhinitis cause mountain cedar pollen within last 2 year document participantreported symptom least last 2 mountain cedar allergy season . Documented skin testing ( prick wheal â‰¥ 4 mm large diluent ) within last 1 year mountain cedar pollen present . Capable read English . Body mass index ( BMI ) &lt; 35 . Any significant medical condition , judgment investigator , contraindication use loratadine , fexofenadine might interfere trial . These may include thyroid disease ( e.g. , hyperthyroidism , hypothyroidism ) , uncontrolled diabetes mellitus , coronary heart disease , ischemic heart disease , elevate intraocular pressure , prostatic hypertrophy . Have start allergen immunotherapy within 1 month precede enrollment participant start allergen immunotherapy anticipate immunotherapy dose change trial . Xolair ( omalizumab ) may use within 4 year prior trial participation . Known allergy intolerance loratadine , desloratadine , fexofenadine . History rhinitis medicamentosa . Use systemic ( oral , rectal , injectable ) , topical ( 1 % topical hydrocortisone permit ) , nasal corticosteroid last 30 day current expect use disallow medication list protocol . Asthma , exception mild intermittent asthma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>